AbCellera and AbbVie Partner to Advance New Antibody Therapies
AbCellera (Nasdaq: ABCL) has initiated a strategic collaboration with AbbVie (NYSE: ABBV) targeting the development of therapeutic antibodies. This multi-year partnership aims to leverage AbCellera's innovative antibody discovery capabilities for up to five targets across various indications. AbCellera will receive research payments, clinical milestones, and royalties from product sales, indicating potential significant revenue streams. CEO Carl Hansen emphasized the collaboration's focus on solving complex antibody discovery challenges to address critical health issues.
- Strategic collaboration with AbbVie, enhancing R&D capabilities.
- Potential revenue from research payments, milestone payments, and royalties.
- Focus on developing therapeutic antibodies for serious health issues.
- None.
“This collaboration with AbbVie is another example of how AbCellera can extend the R&D capabilities for enabled pharmaceutical companies,” said
Under the terms of the agreement, AbbVie has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties on net sales of products.
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.
AbCellera Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005196/en/
Media:
Business Development:
Investor Relations:
Source:
FAQ
What is the recent collaboration between AbCellera and AbbVie about?
What benefits can AbCellera expect from its partnership with AbbVie?
How does the collaboration with AbbVie impact AbCellera's future?